Key points are not available for this paper at this time.
Trastuzumab raises cardiac dysfunction risk, highest with concurrent anthracyclines; leaves open optimal monitoring and sequencing strategies.
Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.5.1156 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11870153 Cardiac Dysfunction in the Trastuzumab Clinical Experience James SpeyerxJames SpeyerSearch for articles by this author Show More New York University Cancer Institute, New York University Medical Center, New York, NY https://doi.org/10.1200/JCO.2002.20.5.1156 Full Text PDF Figures and Tables "Cardiac Dysfunction in the Trastuzumab Clinical Experience." Journal of Clinical Oncology, 20(5), pp. 1156–1157© 2002 by American Society of Clinical Oncology
No takes yet. Share an insight, caveat, or question.
James L. Speyer (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: